ACEi, ARB Use Linked to Lower Risk for Kidney Failure With Replacement Therapy
By Elana Gotkine HealthDay Reporter
MONDAY, July 8, 2024 -- For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a reduced risk for kidney failure with replacement therapy (KFRT) but not death, according to a study published online July 2 in the Annals of Internal Medicine.
Elaine Ku, M.D., from the University of California in San Francisco, and colleagues examined the association of ACEi or ARB treatment initiation with rates of KFRT and death using data from completed randomized controlled trials from 1946 through Dec. 31, 2023.
Data were included for 1,739 participants from 18 trials, and of these patients, 35.9 and 7.6 percent developed KFRT and died, respectively, during a median follow-up of 34 months. The researchers found that the risk for KFRT was lower with ACEi or ARB treatment initiation (adjusted hazard ratio, 0.66; 95 percent confidence interval, 0.55 to 0.79), but the risk for death was not significantly lower (adjusted hazard ratio, 0.86; 95 percent confidence interval, 0.58 to 1.28). No significant interactions were seen between ACEi or ARB treatment and age, estimated glomerular filtration rate, albuminuria, or diabetes.
"Initiation of ACEi or ARB therapy protects against KFRT, but not against death, in people with advanced CKD," the authors write. "Even in an era where other agents, such as sodium-glucose cotransporter-2 inhibitors, are available, significant benefit can be derived from the initiation of ACEi or ARB treatment in patients with low glomerular filtration rate."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Few With Type 2 Diabetes Receive Guideline-Recommended CKD Screening
MONDAY, July 1, 2024 -- Fewer than one-quarter of patients with type 2 diabetes (T2D) receive recommended chronic kidney disease (CKD) screening, according to a study published...
In a Medical First, Kidney Transplant Is Performed With Regional Anesthesia Only
MONDAY, June 24, 2024 -- John Nicolas, a Chicago resident, has become the first person to receive a kidney transplant while awake, according to his doctors at Northwestern...
Triglyceride-Glucose Index Independently Linked to All-Cause Mortality
FRIDAY, June 21, 2024 -- The triglyceride-glucose (TyG) index is independently associated with all-cause mortality among patients with heart failure and chronic kidney disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.